Syndax Pharmaceuticals (SNDX) Stock Forecast, Price & News

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SNDX shares.
View SNDX analyst ratings or view top-rated stocks.

9 Wall Street analysts have issued 12-month target prices for Syndax Pharmaceuticals' shares. Their SNDX share price forecasts range from $28.00 to $43.00. On average, they predict the company's share price to reach $35.70 in the next year. This suggests a possible upside of 182.4% from the stock's current price.
View analysts price targets for SNDX or view top-rated stocks among Wall Street analysts.

Syndax Pharmaceuticals' stock was trading at $25.45 at the start of the year. Since then, SNDX stock has decreased by 50.3% and is now trading at $12.64.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our SNDX earnings forecast.

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) announced its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.09. During the same quarter last year, the business earned ($0.62) earnings per share.

ETFs with the largest weight of Syndax Pharmaceuticals (NASDAQ:SNDX) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR), ALPS Medical Breakthroughs ETF (SBIO) and SPDR S&P Biotech ETF (XBI).Simplify Health Care ETF (PINK).

Based on aggregate information from My MarketBeat watchlists, some companies that other Syndax Pharmaceuticals investors own include OPKO Health (OPK), Exelixis (EXEL), Verastem (VSTM), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Idera Pharmaceuticals (IDRA), TherapeuticsMD (TXMD) and Micron Technology (MU).

(SNDX) raised $66 million in an initial public offering (IPO) on Thursday, March 3rd 2016. The company issued 4,400,000 shares at $14.00-$16.00 per share. Morgan Stanley and Citigroup acted as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.

Syndax Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNDX."

Shares of SNDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SNDX stock can currently be purchased for approximately $12.64.

Syndax Pharmaceuticals (NASDAQ:SNDX) has a market capitalization of $878.23 million and generates $139.71 million in revenue each year. The company earns $-149,340,000.00 in net income (profit) each year or ($2.43) on an earnings per share basis.

The company employs 107 workers across the globe.

Syndax Pharmaceuticals' mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The official website for the company is www.syndax.com. The company can be reached via phone at (781) 419-1400, via email at ir@syndax.com, or via fax at 781-419-1420.